| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-12-20 | Trimodulin® (IgM Concentrate - IgM enriched immunoglobulin) | severe community-acquired pneumonia (sCAP) | 2 | Biotest (Germany) | Infectious diseases |
| 2017-12-20 | bimekizumab | psoriatic arthritis | 2b | UCB (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-12-19 | OSE-127 (Effi-7) | inflammatory bowel diseases including Crohn's disease and ulcerative colitis | preclinical | OSE Immunotherapeutics (France) | Autoimmune diseases - Gastrointestinal diseases - Inflammatory diseases |
| 2017-12-19 | SHP609 (idursulfase-IT) | mucopolysaccharidosis II (MPS II, Hunter Syndrome) | 2-3 | Shire (UK - USA) | Rare diseases - Genetic diseases |
| 2017-12-19 | Traumakine® - FP-1201 (human recombinant interferon-beta 1a) | Multi-Organ Failure (MOF), prevention of surgically operated Ruptured Abdominal Aorta Aneurysm | 2 | Faron Pharmaceuticals (Finland) | Cardiovascular diseases |
| 2017-12-18 | cariprazine | bipolar depression | 3 | Gedeon Richter (Hungary) Allergan (Ireland) | CNS diseases - Mental diseases |
| 2017-12-18 | HLA-A2 CAR lentiviral vector | preclinical | Txcell (France) | Inflammatory diseases | |
| 2017-12-18 | BION-1301 | relapsed or refractory multiple myeloma | 1-2 | Aduro Biotech (USA - CA) | Cancer - Oncology |
| 2017-12-18 | Qarziba®/Isqette® (APN311 - dinutuximab beta) | neuroblastoma | Apeiron Biologics (Austria) | Cancer - Oncology | |
| 2017-12-16 | SEL24 | acute myeloid leukemia | 1-2 | Selvita (Poland) | Cancer - Oncology |
| 2017-12-15 | fitusiran (SAR439774 - ALN-AT3) | hemophilia A, hemophilia B with or without inhibitors | 2 | Alnylam Therapeutics (USA - MA), Sanofi (France) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-15 | fitusiran (SAR439774 - ALN-AT3) | hemophilia A and B with or without inhibitors | 3 | Alnylam Therapeutics (USA - MA), Sanofi (France) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-15 | fitusiran (SAR439774 - ALN-AT3) | hemophilia A and B with or without inhibitors | 3 | Alnylam Therapeutics (USA - MA), Sanofi (France) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-15 | fitusiran (SAR439774 - ALN-AT3) | hemophilia A and B with or without inhibitors | 3 | Alnylam Therapeutics (USA - MA), Sanofi (France) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-14 | hemophilia | Shire (UK - USA) Royal College of Surgeons Ireland (Ireland) Science Foundation Ireland (SFI) (Ireland) Irish Haemophilia Society (Ireland) | Rare diseases - Genetic diseases - Hematological diseases | ||
| 2017-12-14 | PF-04965842 | moderate-to-severe atopic dermatitis (AD) | 3 | Pfizer (USA - NY) | Autoimmune diseases - Dermatological diseases |
| 2017-12-13 | nivolumab and tumor-infiltrating lymphocyte (TIL) | advanced non-small cell lung cancer (NSCLC) | 1 | Iovance Biotherapeutics (USA - CA) tumor-infiltrating lymphocyte (TIL) | Cancer - Oncology |
| 2017-12-13 | REGN2810 - cemiplimab | advanced cutaneous squamous cell carcinoma | 2 | Regeneron Pharmaceuticals (USA - NY) Sanofi (France) | Cancer - Oncology |
| 2017-12-13 | Trumenba® - rLP2086 coadministered with routine meningococcal (groups A, C, Y and W) (MCV4) and tetanus, diphtheria and pertussis (Tdap) vaccines | 3 | Pfizer (USA - NY) | ||
| 2017-12-13 | AVXS-101 (adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene) | spinal muscular atrophy (SMA) Type 1 | 1 | Avexis (USA - IL) | Rare diseases - Genetic diseases - Neuromuscular diseases |
